Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 9, 2010, Pages 1158-1165

  Dolle S ^a   Hoser, D ^a   Rasche, C ^a   Loddenkemper, C ^a   Maurer, M ^a   Zuberbier, T ^a   Worm, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

atopic dermatitis; FoxP3; miltefosine; regulatory T cell; thermographic imaging

Indexed keywords

HYDROCORTISONE; HYDROGALEN; MILTEFOSINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LIPID RAFT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN MANIFESTATION; SKIN PRURITUS; SKIN TINGLING; T LYMPHOCYTE; THERMOGRAPHY;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFLAMMATION; MALE; MEMBRANE MICRODOMAINS; MIDDLE AGED; PHOSPHORYLCHOLINE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955321832     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02341.x     Document Type: Article

References (35)

1. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006 118 : 152 169. (Pubitemid 43946480)
2. Dahten A, Koch C, Ernst D, Schnoller C, Hartmann S, Worm M. Systemic PPARgamma ligation inhibits allergic immune response in the skin. J Invest Dermatol 2008 128 : 2211 2218.
3. Koch C, Dolle S, Metzger M, Rasche C, Jungclas H, Ruhl R et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008 158 : 786 792.
4. Holowka D, Baird B. Fc(epsilon)RI as a paradigm for a lipid raft-dependent receptor in hematopoietic cells. Semin Immunol 2001 13 : 99 105.
5. Surviladze Z, Harrison KA, Murphy RC, Wilson BS. FcepsilonRI and Thy-1 domains have unique protein and lipid compositions. J Lipid Res 2007 48 : 1325 1335.
6. Arthur G, Bittman R. The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta 1998 1390 : 85 102.
7. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008 14 : 2061 2074.
8. van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007 6 : 2337 2345.
9. Unger C, Eibl H. Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug. Lipids 1991 26 : 1412 1417.
10. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992 36 : 1630 1634.
11. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005 83 : 394 395.
12. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006 100 (Suppl 1 S34 S40.
13. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005 366 : 1561 1577.
14. Hochhuth CH, Vehmeyer K, Eibl H, Unger C. Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 1992 141 : 161 168.
15. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 2000 181 : 795 799.
16. Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, dos Santos RV et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol 2009 129 : 496 498.
17. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Arch Dermatol 1980 113 : 663 670.
18. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993 186 : 23 31.
19. Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999 79 : 356 359.
20. Clark AT, Mangat JS, Tay SS, King Y, Monk CJ, White PA et al. Facial thermography is a sensitive and specific method for assessing food challenge outcome. Allergy 2007 62 : 744 749.
21. Larbig M, Burtin B, Martin L, Stamm H, Luettig B, Hohlfeld JM et al. Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine. Br J Clin Pharmacol 2006 62 : 158 164.
22. Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004 122 : 1423 1431.
23. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009 123 : 1124 1133.
24. Delforno C, Holt PJ, Marks R. Corticosteroid effect on epidermal cell size. Br J Dermatol 1978 98 : 619 623.
25. Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 2009 129 : 1878 1891.
26. Clark RA, Kupper TS. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 2007 109 : 194 202.
27. Fujimura T, Okuyama R, Ito Y, Aiba S. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008 158 : 1256 1263.
28. Szegedi A, Barath S, Nagy G, Szodoray P, Gal M, Sipka S et al. Regulatory T cells in atopic dermatitis: epidermal dendritic cell clusters may contribute to their local expansion. Br J Dermatol 2009 160 : 984 993.
29. Vehmeyer K, Scheurich P, Eibl H, Unger C. Hexadecylphosphocholine- mediated enhancement of T-cell responses to interleukin 2. Cell Immunol 1991 137 : 232 238.
30. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007 120 : 744 750 quiz 751-2.
31. Huehn J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009 9 : 83 89.
32. Schnopp C, Rad R, Weidinger A, Weidinger S, Ring J, Eberlein B et al. Fox-P3-positive regulatory T cells are present in the skin of generalized atopic eczema patients and are not particularly affected by medium-dose UVA1 therapy. Photodermatol Photoimmunol Photomed 2007 23 : 81 85.
33. Caproni M, Torchia D, Antiga E, Volpi W, del Bianco E, Fabbri P. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006 26 : 370 375.
34. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 54 : 1 15 quiz 16-8.
35. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 2008 5 : 11.